Supriya Lifescience Limited – Investor Presentation Summary

Key Operational Highlights

  • 40+ APIs in product portfolio with operations across 120+ countries
  • Manufacturing facility spread across 35,000 sq.mts with 932 KLPD reactor capacity
  • 82% of FY26 revenue came from exports with over 1,500 customers globally
  • Key drivers include new product launches in Cardiovascular and ADHD segments, geographic expansion, and backward integration initiatives

Segment-wise Performance

  • Performance by therapy areas not specifically quantified in revenue breakdown
  • Cardiovascular segment: Key product launched in Q3FY26, revenue contribution started in Q4FY26
  • ADHD segment: Key product launched with strong demand from LATAM and Europe
  • Liquid Anesthetic: Commercialized with steady monthly supplies underway

Financial Highlights

  • Revenue: ₹8,278.7 million (FY26), ₹6,964.8 million (FY25) - 18.9% YoY growth
  • Q4 Revenue: ₹2,765.3 million (Q4 FY26), ₹1,841.1 million (Q4 FY25) - 50.2% YoY growth
  • EBITDA: ₹2,940.5 million (FY26), ₹2,607.9 million (FY25) - 12.8% YoY growth
  • Q4 EBITDA: ₹976.2 million (Q4 FY26), ₹675.8 million (Q4 FY25) - 44.4% YoY growth
  • PAT: ₹2,091.2 million (FY26), ₹1,879.6 million (FY25) - 11.3% YoY growth
  • Q4 PAT: ₹742.3 million (Q4 FY26), ₹503.7 million (Q4 FY25) - 47.4% YoY growth
  • EPS: ₹25.98 (FY26), ₹23.35 (FY25)
  • Q4 EPS: ₹9.22 (Q4 FY26), ₹6.29 (Q4 FY25)
  • EBITDA Margin: 35.5% (FY26), 37.4% (FY25) - 192 bps decline
  • PAT Margin: 25.3% (FY26), 27.0% (FY25) - 173 bps decline
  • Drivers: Higher revenue growth offset by increased cost of goods sold (20.3% YoY increase) and other expenses (27.2% YoY increase)
  • Exceptional items: ₹4.6 million in FY26

Geographical Revenue Split

  • Domestic vs Export: 82% of FY26 revenue from exports
  • Regional breakdown: Strong demand from LATAM and Europe markets specifically mentioned

Balance Sheet Snapshot

  • Total Assets: ₹13,571 million (FY26), ₹11,123 million (FY25)
  • Property, Plant and Equipment: ₹6,833 million (FY26), ₹4,468 million (FY25)
  • Inventories: ₹1,596 million (FY26), ₹1,183 million (FY25)
  • Trade Receivables: ₹2,194 million (FY26), ₹1,344 million (FY25)
  • Cash and Cash Equivalents: ₹375 million (FY26), ₹761 million (FY25)
  • Total Equity: ₹11,977 million (FY26), ₹9,968 million (FY25)
  • Net Debt/Equity: Minimal debt position with focus on equity financing
  • Working Capital: Increased inventory and receivables reflecting business expansion

Capex & Cash Flow Health

  • Capital Expenditure: Significant investments in property, plant and equipment (₹6,833 million in FY26 vs ₹4,468 million in FY25)
  • Strategic land acquisitions: 12,551 sq.mt adjacent to existing facility, 24,646 sq.mt for backward integration, 80,000 sq.mt at Isambe, Patalganga
  • Free Cash Flow: Not specifically disclosed
  • Investment Rationale: Focus on capacity expansion, backward integration, and new facility development

Strategic & R&D Initiatives

  • R&D Centers: Ambernath API R&D facility with 16 scientists, Finished Dosage R&D with 30 products under development
  • New Product Development: 3-4 APIs developed annually using cost-competitive technologies
  • Patent Filings: Two patents filed this year, including novel Semaglutide tablet formulation
  • Capacity Enhancement: New vitamin product block commissioned, civil work for debottlenecking, new F block addition planned
  • Five finished dosage manufacturing lines operational, new nasal line planned

Industry Trends & Business Environment

  • Global API market presence with focus on regulated markets
  • Regulatory compliance emphasis with WHO-GMP, Written Confirmation, ISO, Halal certifications
  • Increasing demand for niche pharmaceutical products in international markets

Management Commentary & Growth Outlook

  • FY27 Product Pipeline: Planning ~2 launches each in Anesthetic and ADHD segments
  • Market Expansion: Regulatory filings in EU and US underway, agreements in South Asia, supplies initiated for ROW markets
  • CMO/CDMO Opportunities: Evaluating exclusive manufacturing rights for liquid inhalation products, GLP-1 portfolio development in progress
  • Regulatory Approvals: EU-GMP, COFEPRIS, Health Canada approvals in progress, plan to file six dossiers in EU during current financial year
  • Customer Concentration: Plan to further reduce concentration through penetration to newer geographies and adding new niche products